Marie McDonald
Net worth: 556 117 $ as of 2026-05-30
Net worth: 556 117 $ as of 2026-05-30
Marie McDonald is currently an Independent Non-Executive Director at CSL Ltd. since 2013, an Independent Non-Executive Director at Nanosonics Ltd. since 2016, a Non-Executive Director at The Walter & Eliza Hall Institute of Medical Research since 2016, an Independent Non-Executive Director at Nufarm Ltd. since 2017, a Director at The Melbourne University Law School Foundation since 2021, and a Non-Executive Director at Telix Pharmaceuticals Ltd. starting in 2025.
Former roles include Member of the Australia Takeovers Panel from 2001 to 2010, National Head-Mergers & Acquisitions at Law Council of Australia Ltd. from 2012 to 2013, and Senior Partner at Ashurst Australia from 1990 to 2014.
Education was completed at the University of Melbourne with undergraduate and graduate degrees.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2025-08-28 | 4,457 ( 0% ) | 309 810 $ | 2026-05-30 | |
NANOSONICS LIMITED 0.02% | 2025-06-29 | 50,106 ( 0.02% ) | 113 922 $ | 2026-05-30 |
NUFARM LIMITED 0.01% | 2025-09-29 | 45,179 ( 0.01% ) | 97 519 $ | 2026-05-30 |
| 2026-05-25 | 3,719 ( 0% ) | 34 866 $ | 2026-05-30 |
| Companies | Position | Start |
|---|---|---|
| CSL LIMITED | Director/Board Member | 2013-08-13 |
| NANOSONICS LIMITED | Director/Board Member | 2016-10-23 |
| NUFARM LIMITED | Director/Board Member | 2017-03-21 |
| TELIX PHARMACEUTICALS LIMITED | Director/Board Member | 2025-03-02 |
The Walter & Eliza Hall Institute of Medical Research
The Walter & Eliza Hall Institute of Medical Research Miscellaneous Commercial ServicesCommercial Services Provides medical research services | Director/Board Member | 2016-09-30 |
The Melbourne University Law School Foundation | Director/Board Member | 2021-09-30 |
| Companies | Position | End |
|---|---|---|
Ashurst Australia
Ashurst Australia Miscellaneous Commercial ServicesCommercial Services Provides legal services | Corporate Officer/Principal | 2014-06-30 |
Law Council of Australia Ltd.
Law Council of Australia Ltd. Miscellaneous Commercial ServicesCommercial Services Operates law firms | Corporate Officer/Principal | 2012-12-31 |
Australia Takeovers Panel
Australia Takeovers Panel General GovernmentGovernment Resolves disputes about a takeover bid until the bid period has ended | Corporate Officer/Principal | 2009-12-31 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 10 |
|---|---|
CSL Ltd.
CSL Ltd. BiotechnologyHealth Technology Develops and manufactures medicines that treat people with rare and serious diseases | Health Technology |
Australia Takeovers Panel
Australia Takeovers Panel General GovernmentGovernment Resolves disputes about a takeover bid until the bid period has ended | Government |
Nanosonics Ltd.
Nanosonics Ltd. Medical SpecialtiesHealth Technology Engages in the research, development and commercialization of infection control and decontamination products and related technologies | Health Technology |
The Walter & Eliza Hall Institute of Medical Research
The Walter & Eliza Hall Institute of Medical Research Miscellaneous Commercial ServicesCommercial Services Provides medical research services | Commercial Services |
Nufarm Ltd.
Nufarm Ltd. Chemicals: AgriculturalProcess Industries Manufactures and markets agricultural crop protection products | Process Industries |
University of Melbourne
University of Melbourne Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Law Council of Australia Ltd.
Law Council of Australia Ltd. Miscellaneous Commercial ServicesCommercial Services Operates law firms | Commercial Services |
Ashurst Australia
Ashurst Australia Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
The Melbourne University Law School Foundation | |
Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Ltd. BiotechnologyHealth Technology Operates as a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals | Health Technology |
Select your edition
All financial news and data tailored to specific country editions